Nicholas van As
@nickva1
Followers
2K
Following
2K
Media
165
Statuses
1K
Medical Director @royalmarsdenNHS Oncologist, Professor @ICR_London dad to 4, pretend cyclist (views my own)
London, England
Joined March 2009
PACE-C safety results at 2y by Ratnu Ratnakumaran SBRT vs mod hypofx for int/high-risk #ProstateCancer RT + ADT SBRT had ⬆️rates of moderate/modest (grade 2) impact on GU function but no sig diff for GI #ASTRO25 @alison_tree @nickva1 @RMresearch_ @ICR_London @ASTRO_org
1
8
30
Main difference was that #PACEB was designed as non inferiority trial at 5 years, so we had to wait. I expect we will see no difference in BCF at 5 years in #GU005 (unlikely to be superior)… let’s see at 10-15 years. QoL data, very interesting. More work to do!
Or maybe don’t report biochemical outcomes before 5y median FU when it is well known that benign bounces make BF estimates unreliable <5y That’s why Widmark and @nickva1 both waited.
1
0
6
Main difference was that #PACEB was designed as non inferiority trial at 5 years, so we had to wait. I expect we will see no difference in BCF at 5 years in #GU005 (unlikely to be superior)… let’s see at 10-15 years. QoL data, very interesting. More work to do!
@DrAndrewLoblaw @nickva1 I generally agree, but futility allowed reporting now. The QoL endpoints are of value by themselves and you’d have to report BcR, but with strong caveats needed.
1
0
1
Way past your bedtime
1
0
2
Good luck 🤞
1
0
2
New review led by @DeepOnco of @royalmarsdenNHS outlines global trends and evolving diagnostics, treatment, and surveillance of #ProstateCancer. Read: https://t.co/AUAGW1mzrM
@PCaParker @AmarUKishan @VedangMurthy @nickva1 @alison_tree @APCCC_Lugano @ICR_London
2
28
74
Delighted to share our comprehensive review on #ProstateCancer, now out in @CACancerJournal , the highest-impact STEM journal. Huge thanks to an amazing team ! @alison_tree @PCaParker @AmarUKishan @VedangMurthy @nickva1 @royalmarsdenNHS @ICR_London Link: https://t.co/emj35K7B4y
5
41
118
Fantastic science! Congrats Nick Turner at team @royalmarsdenNHS
#ASCO25 plenary 🚨 SERENA-6 🦾First ctDNA-guided switch trial in HR+/HER2– #breastcancer ➡️ ESR1m detected via ctDNA during 1L AI + CDK4/6i ➡️Switch to camizestrant + CDK4/6i ⬇️ PFS HR 0.44 👍🏼mPFS: 16.0 vs 9.2 mo 👍🏼12-mo PFS: 61% vs 33% ⚖️ low toxicity, low d/c for AEs #bcsm
0
0
2
#ASCO25 plenary 🚨 SERENA-6 🦾First ctDNA-guided switch trial in HR+/HER2– #breastcancer ➡️ ESR1m detected via ctDNA during 1L AI + CDK4/6i ➡️Switch to camizestrant + CDK4/6i ⬇️ PFS HR 0.44 👍🏼mPFS: 16.0 vs 9.2 mo 👍🏼12-mo PFS: 61% vs 33% ⚖️ low toxicity, low d/c for AEs #bcsm
0
2
7
Gorgeous horse!! #nobias
0
0
3
0
0
2
Delighted to have been invited to attend a reception with colleagues from @royalmarsdenNHS in recognition of cancer support at Buckingham Palace with TM The King and Queen.@RoyalFamily Thanks for supporting the work we do.
6
23
210
We're hiring! Clinical Oncology Research Fellow opportunity at @royalmarsdenNHS @ICR_London to work on the landmark PACE trial & future prostate radiotherapy studies. Work with me, @EmmaHall71 @y_suhughes Join us! #OncologyJobs
https://t.co/bB9xAA3kfN
@alison_tree @cpeedell
0
5
11
Thank you @EUplatinum we are delighted with this recognition. I am grateful to the team and particularly the patients that made it possible! @alison_tree @EmmaHall71 @cpeedell @DrAndrewLoblaw @ICR_London @royalmarsdenNHS
0
0
14
Just brilliant!!
0
0
10
In case you may have missed any of the Virtual Grand Rounds in Radiation Oncology lectures Recordings are 👇 https://t.co/z4dL8OGMcs Endorsed by: @ESTRO_RT
@degro_ev SASRO
1
33
98
View our top 5 articles of the week: @NCCN @DrCrystalD
@MOliveira_MD @CharuAggarwalMD
@HatimHusainMD @ReckampK
@DanengLi @nickva1 1. https://t.co/Vz9zpa9deZ 2. https://t.co/9hcA6V1NLw 3. https://t.co/MGEnHswhvO 4. https://t.co/Eov648gzjL 5. https://t.co/vAU0LO1N8T
0
3
8